ITPP as an adjunctive treatment for progressive respiratory failure in COVID-19 and other pulmonary parenchymal infections - a randomized, double-blind, non-commercial phase II clinical trial [BREATH2]

Status

Completed

Phases

Phase 2

Study type

Interventional

Source

EU CTIS

Registry ID

CTIS2024-517878-21-00

Acronym

ABM/COVID19/0034

Enrollment

100

Registered

2025-01-11

Start date

2023-11-28

Completion date

2025-06-11

Last updated

2025-02-10

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

COVID-19 and other pulmonary parenchyma infections.

Brief summary

Improvement of respiratory capacity in patients who receive ITPP as adjunct therapy, as measured by an improvement in gasometric and biochemical parameters.

Detailed description

Determination of the ITPP safety profile and tolerance.

Interventions

DRUGOXY111A

DRUGInjectio Natrii Chlorati Isotonica Polpharma

DRUG9 mg/ml

DRUGrozpuszczalnik do sporządzania leków parenteralnych

Eligibility

Sex/Gender

All

Age

18 Years to No maximum

Design outcomes

Primary

Measure	Time frame
Improvement of respiratory capacity in patients who receive ITPP as adjunct therapy, as measured by an improvement in gasometric and biochemical parameters.	—

Secondary

Measure	Time frame
Determination of the ITPP safety profile and tolerance.	—

Countries

Poland

Outcome results

None listed

Source: EU CTIS · Data processed: Feb 4, 2026